Opinion

Video

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

Author(s):

Kelly E. McCann, MD, PhD,Sara A. Hurvitz, MD, FACP

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

Related Videos
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
1 expert in this video
1 expert in this video
David Rimm, MD, PhD
Vered Stearns, MD
1 expert in this video
1 expert in this video
Ruth M. O’Regan, MD
Related Content
Breast Cancer
November 27th 2024

Adjuvant Ribociclib Wins EU Approval for HR+/HER2– Early Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

The OncFive: Top Oncology Articles for the Week of 11/17
November 23rd 2024

The OncFive: Top Oncology Articles for the Week of 11/17

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, Diana Hyland Chair for Breast Cancer, University Hospitals Seidman Cancer Center
November 20th 2024

STK-478 May Be an Effective, Tolerable Treatment Alternative in PIK3CA-Mutant Breast and Gynecologic Cancers

Lubna Naaz Chaudhary, MD, MS, associate professor, medicine, Medical College of Wisconsin
November 19th 2024

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer